Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RinGlusin vs Apidra Immunogenicity in T1DM
NCT07070752Phase 3Completed
- Sponsor
- Geropharm
- Start
- Apr 2023
- Primary completion
- Nov 2023
- Modality
- Insulin and Analogs
- Countries
- 1
01
Overview
A Phase 3 trial of RinGlusin in type 1 diabetes mellitus (T1D), sponsored by Geropharm. Started Apr 2023; status: completed.
02
Drugs
RinGlusin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07070752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07070752.